DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

SHA:603233 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	18,028	17,151	28,359	37,585	33,307	51,603
Market Cap Growth	-23.10%	-39.52%	-24.55%	12.85%	-35.46%	89.92%
Enterprise Value	19,398	20,006	31,251	40,044	35,732	49,307
Last Close Price	15.52	14.77	23.44	30.48	26.60	40.76
PE Ratio	18.36	18.75	24.31	36.29	42.10	48.58
Forward PE	17.19	16.44	23.76	31.37	28.06	49.98
PS Ratio	0.68	0.65	1.16	1.77	1.99	3.54
PB Ratio	2.09	2.11	3.58	5.48	5.61	9.26
P/TBV Ratio	9.57	12.20	14.61	11.71	11.90	14.49
P/FCF Ratio	7.55	10.52	20.59	13.81	128.08	44.42
P/OCF Ratio	4.94	5.52	8.94	10.01	21.42	26.41
EV/Sales Ratio	0.73	0.76	1.27	1.89	2.13	3.38
EV/EBITDA Ratio	6.01	6.39	9.63	22.15	27.36	32.16
EV/EBIT Ratio	12.05	12.93	17.40	25.18	32.45	36.19
EV/FCF Ratio	8.12	12.27	22.69	14.71	137.41	42.45
Debt / Equity Ratio	0.79	0.95	0.82	0.86	0.89	0.25
Debt / EBITDA Ratio	2.12	2.47	2.01	2.06	2.34	0.91
Debt / FCF Ratio	2.86	4.75	4.73	2.18	20.29	1.21
Asset Turnover	1.02	1.05	1.09	1.11	1.13	1.39
Inventory Turnover	4.16	4.19	3.92	3.53	3.29	3.80
Quick Ratio	0.62	0.58	0.54	0.62	0.55	0.93
Current Ratio	0.97	0.92	0.94	1.10	1.10	1.52
Return on Equity (ROE)	11.98%	12.20%	16.63%	16.86%	13.98%	21.87%
Return on Assets (ROA)	3.86%	3.83%	4.99%	5.21%	4.64%	8.11%
Return on Capital (ROIC)	6.55%	6.38%	8.24%	8.28%	7.57%	14.64%
Return on Capital Employed (ROCE)	12.30%	12.20%	14.20%	14.30%	10.80%	19.90%
Earnings Yield	5.42%	5.33%	4.11%	2.76%	2.38%	2.06%
FCF Yield	13.25%	9.51%	4.86%	7.24%	0.78%	2.25%
Dividend Yield	3.89%	4.20%	1.32%	1.64%	1.31%	1.14%
Payout Ratio	77.87%	82.34%	51.82%	40.58%	67.53%	31.38%
Buyback Yield / Dilution	-0.15%	0.28%	0.50%	-0.69%	0.24%	-2.65%
Total Shareholder Return	3.75%	4.48%	1.82%	0.95%	1.54%	-1.51%

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.